A recent congressional hearing on 340B is the latest iteration of a standoff between two pillars of the healthcare industry—hospitals and pharmaceutical manufacturers—both of which have powerful ...

2022 was an eventful year on the 340B front, packed with updates to consequential litigation, proposed new rules, ongoing uncertainty into the Health Resources and Services Administration's (HRSA) ...

Amid ongoing controversy over 340B drug discounts, a sweeping review suggests the program is doing what it was intended to do: generate revenue for hospitals, clinics and pharmacies by requiring ...

The 340B drug discount program incentivizes hospitals to purchase outpatient clinics and prescribe more and higher-cost drugs — behaviors that tend to increase costs for the federal government and ...

Despite the rancor, there are many bipartisan opportunities for the divided 118 th Congress. Near the top of the to-do list should be reforming the well-intentioned, but poorly designed, 340B drug ...

As we enter into the final months of 2024, new developments in the administration of the 340B Drug Pricing Program signal that additional reform may be on the way. Although recent revisions to the ...

As policymakers weigh changes to the 340B Drug Discount Program, which allows certain hospitals and clinics to purchase drugs at discounted prices, they have sought information on the size of the ...

Drug companies are at it again. They will not relent in their multiyear campaign to dismantle the 340B Drug Pricing Program. Drug companies are at it again. They will not relent in their multiyear ...

Senator calls on Congress to increase oversight of the 340B Drug Pricing Program by requiring participating providers to complete annual reports on program savings and revenues. If your health system ...

The 340B Drug Pricing Program helps poor states like Kentucky. Bigstock Senate Bill 14 in the ongoing Kentucky legislative session relates to the federal 340B Drug Pricing Program. This program ...